The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis.
about
Structural Studies of Pterin-Based Inhibitors of Dihydropteroate SynthaseCrystal structures of Burkholderia cenocepacia dihydropteroate synthase in the apo-form and complexed with the product 7,8-dihydropteroateStructure-Based Design of Novel Pyrimido[4,5-c]pyridazine Derivatives as Dihydropteroate Synthase Inhibitors with Increased AffinityDiscovery of Potent and Selective Inhibitors of Toxoplasma gondii Thymidylate Synthase for Opportunistic InfectionsComparative genomics analysis of Mycobacterium ulcerans for the identification of putative essential genes and therapeutic candidatesTargeting purine and pyrimidine metabolism in human apicomplexan parasitesRepurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolyticaCommunication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence.The role of DNA microarrays in Toxoplasma gondii research, the causative agent of ocular toxoplasmosis.Metabolic reconstruction identifies strain-specific regulation of virulence in Toxoplasma gondii.Inhibitory effect of aureobasidin A on Toxoplasma gondiiRegulation of CD8+ T cell responses to infection with parasitic protozoa.Metabolic pathway analysis and molecular docking analysis for identification of putative drug targets in Toxoplasma gondii: novel approachGenetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil.Examination of intrinsic sulfonamide resistance in Bacillus anthracis: a novel assay for dihydropteroate synthase.Prevention and treatment of congenital toxoplasmosis.Pathogenicity and phenotypic sulfadiazine resistance of Toxoplasma gondii isolates obtained from livestock in northeastern BrazilSulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters.The origins of apicomplexan sequence innovation.Drugs in development for toxoplasmosis: advances, challenges, and current status.Dihydrofolate reductase inhibitors: developments in antiparasitic chemotherapy.1,4-Disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferation.In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.An atypical orthologue of 6-pyruvoyltetrahydropterin synthase can provide the missing link in the folate biosynthesis pathway of malaria parasites.Evaluation of Anti-Toxoplasma gondii Effect of Ursolic Acid as a Novel Toxoplasmosis Inhibitor.Drug Resistance in
P2860
Q27658109-6533BCF4-3749-4EC8-8638-9AECB77F08F8Q27667765-A28D9071-3E60-4D0D-BA08-75CD22417FB2Q27678040-DFBA7481-555B-4C9F-B2E1-D82781394AF3Q27681485-A8FDD5A8-2C0A-4E38-BDB2-973762077131Q28482216-4C9692F6-307F-4C50-B07E-A0696EC120BEQ28629739-1106AC6C-4E5B-44FD-BD9E-D67611ED23B5Q30487158-E2D6DECC-AEE2-4771-939E-B34501AC7B67Q33606893-922413F0-0E6B-44F6-A653-960F448C583FQ33631447-666CE9FA-FDC4-4284-840A-7CEBBE16712AQ33689651-64AE6716-8CD8-4A8A-9E2E-A4234615992EQ33769976-BDB74CD3-7867-4B34-8265-B364DAE62BF2Q34108177-6B510E08-310D-47D4-8584-57DA4F7103F2Q35770264-A32708B2-3975-4C9E-BE1B-4622285C4563Q36258864-82C97193-162E-4052-8F45-2670C7630ACDQ36744550-881C29B1-0C24-4ACE-A423-E7D441CB0D30Q36777857-43064BD3-7FBE-4F18-9E70-B6EE5AD92483Q37007536-3BBB0F3C-6E60-473A-97C4-998BB739FAEBQ37032988-0C64B095-0807-4F28-854A-B649E61D79D8Q37247038-BF576556-6AFE-4ECA-8D6B-BC6A0899A941Q37613765-EDD8E499-D391-4D3B-BCE0-25B11EE4DA55Q37765574-7F73CAA4-2C70-4D98-914A-F9426263CAFAQ38976714-F50E339C-CC33-463E-BCFA-57C5D68AE318Q41831157-A4704BA9-0E3C-40E6-BA4B-8793918E73D2Q41940305-3EDDB0E9-5557-47BB-B712-CA2EC305A125Q54215294-135578E2-6AA6-4398-A161-DBF8C0C1602EQ58699076-18C3E0E3-86F3-440D-A64D-CE9C7661FD0C
P2860
The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The molecular basis of sulfona ...... l management of toxoplasmosis.
@en
The molecular basis of sulfona ...... l management of toxoplasmosis.
@nl
type
label
The molecular basis of sulfona ...... l management of toxoplasmosis.
@en
The molecular basis of sulfona ...... l management of toxoplasmosis.
@nl
prefLabel
The molecular basis of sulfona ...... l management of toxoplasmosis.
@en
The molecular basis of sulfona ...... l management of toxoplasmosis.
@nl
P2093
P356
P1476
The molecular basis of sulfona ...... l management of toxoplasmosis.
@en
P2093
David H M Joynson
Edward Guy
John E Hyde
Paul F G Sims
Tanya V Aspinall
P304
P356
10.1086/340577
P407
P577
2002-05-17T00:00:00Z